{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T15:39:16Z","timestamp":1792683556925,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","lungcancerjournal.info","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.lungcan.2018.10.001","type":"journal-article","created":{"date-parts":[[2018,10,3]],"date-time":"2018-10-03T17:25:20Z","timestamp":1538587520000},"page":"212-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":136,"special_numbering":"C","title":["Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8909-5709","authenticated-orcid":false,"given":"Teppei","family":"Yamaguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takaaki","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitsugu","family":"Horio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Inaba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1788-559X","authenticated-orcid":false,"given":"Yasushi","family":"Yatabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Hida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2018.10.001_bib0005","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1097\/01.mcp.0000170521.71497.ba","article-title":"Does interstitial lung disease predispose to lung cancer?","volume":"11","author":"Daniels","year":"2005","journal-title":"Curr. Opin. Pulm. Med."},{"issue":"Suppl. (2)","key":"10.1016\/j.lungcan.2018.10.001_bib0010","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.bjc.6602061","article-title":"The epidemiology of interstitial lung disease and its association with lung cancer","volume":"91","author":"Raghu","year":"2004","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0015","article-title":"Prevalence of lung cancer in patients with interstitial lung disease is higher than in those with chronic obstructive pulmonary disease","volume":"97","author":"Jung","year":"2018","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0020","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1164\/rccm.200710-1501OC","article-title":"Interstitial lung disease in Japanese patients with lung cancer: a cohort and nested case-control study","volume":"177","author":"Kudoh","year":"2008","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0025","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1093\/jjco\/hyl021","article-title":"Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs","volume":"36","author":"Niho","year":"2006","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0030","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/j.1440-1843.2009.01666.x","article-title":"Clinical characteristics of acute respiratory deterioration in pulmonary fibrosis associated with lung cancer following anti-cancer therapy","volume":"15","author":"Isobe","year":"2010","journal-title":"Respirology"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0035","doi-asserted-by":"crossref","first-page":"665","DOI":"10.2169\/internalmedicine.48.1650","article-title":"Exacerbation of idiopathic interstitial pneumonias associated with lung cancer therapy","volume":"48","author":"Minegishi","year":"2009","journal-title":"Intern. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0040","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1097\/JTO.0000000000000187","article-title":"Combined analysis of V20, VS5, pulmonary fibrosis score on baseline computed tomography, and patient age improves prediction of severe radiation pneumonitis after concurrent chemoradiotherapy for locally advanced non-small-cell lung cancer","volume":"9","author":"Tsujino","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0045","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1093\/intimm\/dxm091","article-title":"Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs","volume":"19","author":"Wong","year":"2007","journal-title":"Int. Immunol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1056\/NEJMoa1305133","article-title":"Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma","volume":"369","author":"Hamid","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0055","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0060","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0065","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0070","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0075","doi-asserted-by":"crossref","first-page":"977","DOI":"10.2214\/ajr.169.4.9308447","article-title":"Thin-section CT obtained at 10-mm increments versus limited three-level thin-section CT for idiopathic pulmonary fibrosis: correlation with pathologic scoring","volume":"169","author":"Kazerooni","year":"1997","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0080","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1164\/rccm.2009-040GL","article-title":"ATS\/ERS\/JRS\/ALAT committee on idiopathic pulmonary fibrosis, an official ATS\/ERS\/JRS\/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management","volume":"183","author":"Raghu","year":"2011","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0085","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1378\/chest.120.3.725","article-title":"CT assessment of subtypes of pulmonary emphysema in smokers","volume":"120","author":"Satoh","year":"2001","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0090","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010). U.S. Department of Health and Human Services, National Institute of Health National Cancer Institute. Available at https:\/\/www.eortc.be\/services\/doc\/ctc\/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on 15 September 2018)."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0095","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.athoracsur.2015.03.094","article-title":"Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia","volume":"100","author":"Omori","year":"2015","journal-title":"Ann. Thorac. Surg."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2017.06.008","article-title":"A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia","volume":"111","author":"Fujimoto","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0105","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.lungcan.2016.12.016","article-title":"Nivolumab-induced interstitial lung disease analysis of two phase II studies patients with recurrent or advanced non-small-cell lung cancer","volume":"104","author":"Kato","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0110","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1164\/ajrccm.162.3.9907120","article-title":"Computed tomographic measurements of airway dimensions and emphysema in smokers. Correlation with lung function","volume":"162","author":"Nakano","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0115","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/ajrccm.158.2.9709008","article-title":"Pulmonary function tests and CT scan in the management of idiopathic pulmonary fibrosis","volume":"158","author":"Xaubet","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0120","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","article-title":"Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy","volume":"35","author":"Naidoo","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0125","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","article-title":"Pembrolizumab cutaneous adverse events and their association with disease progression","volume":"151","author":"SanlorenzoM","year":"2015","journal-title":"JAMA Dermatol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0130","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/1346-8138.13520","article-title":"Correlation between vitiligo occurrence and clinical benefit in advanced melanoma patients treated with nivolumab: a multi-institutional retrospective study","volume":"44","author":"Nakamura","year":"2016","journal-title":"J. Dermatol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0135","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1001\/jamaoncol.2017.2925","article-title":"Association of immune-related adverse events with nivolumab efficacy in non-small-cell lung cancer","volume":"4","author":"Haratani","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","article-title":"Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab","volume":"115","author":"Sato","year":"2018","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0145","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1056\/NEJMc1008506","article-title":"Interstitial lung disease and gefitinib","volume":"363","author":"Murashige","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0150","doi-asserted-by":"crossref","first-page":"93149","DOI":"10.18632\/oncotarget.18703","article-title":"Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis","volume":"8","author":"Kim","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0155","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3389\/fphar.2017.00730","article-title":"Immune-related adverse events associated with anti-PD-1\/PD-L1 treatment for malignancies: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0160","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1001\/jamaoncol.2016.2453","article-title":"Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced Cancer: a systematic review and meta-analysis","volume":"2","author":"Nishino","year":"2016","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0165","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jtho.2016.06.006","article-title":"Clinical significance of PD-L1 protein expression in surgically resected primary lung adenocarcinoma","volume":"11","author":"Takada","year":"2016","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0170","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0175","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.cell.2012.08.024","article-title":"Genomic landscape of non-small cell lung cancer in smokers and never-smokers","volume":"150","author":"Govindan","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.lungcan.2018.10.001_bib0180","doi-asserted-by":"crossref","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","article-title":"First-line nivolumab in stage IV or recurrent non-small-cell lung cancer","volume":"376","author":"Carbone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2018.10.001_bib0185","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/j.cllc.2018.01.004","article-title":"Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: a subgroup analysis of the phase 3 OAK study","volume":"19","author":"Hida","year":"2018","journal-title":"Clin. Lung Cancer"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305853?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500218305853?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,11,11]],"date-time":"2020-11-11T23:53:54Z","timestamp":1605138834000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500218305853"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":37,"alternative-id":["S0169500218305853"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.001","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2018.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}